Emmaus Life Sciences annual return on equity
2017
2018
Emmaus Life Sciences Return on Equity (ROE) Growth & History (EMMA)
Emmaus Life Sciences's return on equity was −224.05% for fiscal 2018.
View full Emmaus Life Sciences company overviewEmmaus Life Sciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2018 · Sep 30 | 2018-09-30 | −224.05% | +184.39 pp |
| 2017 | 2017-09-30 | −408.44% | — |
Emmaus Life Sciences quarterly return on equity
Q2.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q2.19
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2019 | 2019-06-30 | −604.15% | −498.94 pp |
| Q4 2018 | 2018-09-30 | 408.34% | +555.70 pp |
| Q3 2018 | 2018-06-30 | −105.22% | — |
| Q2 2018 | 2018-03-31 | −130.46% | +344.67 pp |
| Q1 2018 | 2017-12-31 | −82.95% | — |
| Q4 2017 | 2017-09-30 | −147.36% | — |
| Q2 2017 | 2017-03-31 | −475.13% | — |
Emmaus Life Sciences return on equity trends
Between the periods ended 2017-09-30 and 2018-09-30, Emmaus Life Sciences's return on equity increased from −408.44% to −224.05%, a change of +184.39 percentage points. The latest reported quarter, Q2 2019, shows −604.15%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Emmaus Life Sciences source filings ↗